Pluvicto: Clinical Trials

8 trials of Pluvicto, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 2 completed, 2 not yet recruiting, 1 active not recruiting. 8 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Recruiting 3, Completed 2, Not yet recruiting 2, Active not recruiting 1
Phase 21Not yet recruiting 1

Follow Pluvicto: new trials by email Literature Review of Pluvicto trials Research Report on Pluvicto

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer
Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Phase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research Group4322027-01-062026-10-01
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Lu-177 PSMA-617 - Metastatic Renal Cancer
Phase 3Not yet recruitingAnkara University202026-05-012026-02-27
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 3RecruitingAlliance for Clinical Trials in Oncology15242026-03-312026-11-03
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
177Lu-PMSA-617, Standard of Care - Prostate Cancer Metastatic
Phase 3RecruitingUNICANCER5002024-09-122024-12-20
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
Stereotactic Ablative Body Radiotherapy (SABR), 177Lu-PSMA-617, Androgen Deprivation Therapy (ADT) - Prostate Cancer Metastatic
Phase 3RecruitingUniversity College, London33602024-06-112025-09-26
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT - Prostatic Neoplasms
Phase 3CompletedNovartis Pharmaceuticals4692021-06-152026-11-04
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT - Prostatic Neoplasms
Phase 3Active not recruitingNovartis Pharmaceuticals11442021-06-092026-11-04
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
177Lu-PSMA-617, Best supportive/best standard of care - Prostate Cancer
Phase 3CompletedEndocyte8612018-05-292025-01-13

Conditions studied

Prostatic Neoplasms (5)  ·  Carcinoma, Renal Cell (1)  ·  Genital Diseases, Male (1)  ·  Kidney Neoplasms (1)  ·  Prostatic Diseases (1)

Sponsors

Novartis Pharmaceuticals (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Ankara University (1)  ·  ECOG-ACRIN Cancer Research Group (1)  ·  Endocyte (1)  ·  UNICANCER (1)  ·  University College, London (1)

Countries

France (4)  ·  United Kingdom (4)  ·  United States (4)  ·  Belgium (3)  ·  Canada (3)  ·  Germany (3)  ·  Netherlands (3)  ·  Sweden (3)  ·  Austria (2)  ·  Czechia (2)  ·  Denmark (2)  ·  Poland (2)  ·  Spain (2)  ·  Switzerland (2)  ·  China (1)

Top investigators

Louise Brown (1)  ·  Michael Schweizer (1)  ·  Nick James (1)  ·  Thomas Hope, MD (1)

Results publications

PMID 31595044, PMID 33189510, PMID 34161051, PMID 37230533, PMID 37269841, PMID 38050121, PMID 38185538, PMID 38534939, PMID 39031642, PMID 39162634, PMID 39242323, PMID 39293462, PMID 39430616, PMID 40441170, PMID 40680993, PMID 41979224, PMID 42561994

NIH funding

2023 (2), 2018 (1), U10CA180820 (1)